Press releases | WebDisclosure

PRESS RELEASE

published on 09/11/2024 at 07:30, 1 year 4 months ago

Selfio smoothing the path to funding from the Kreditanstalt für Wiederaufbau (KfW)
Selfio SE, a subsidiary of 3U HOLDING AG, launches a comprehensive KfW funding service to simplify government funding applications for heating systems. More information available on the Selfio website and YouTube channel

3U HOLDING AG Selfio SE KfW Funding Service Government Funding Applications Heating Systems
PRESS RELEASE

published on 09/11/2024 at 07:30, 1 year 4 months ago

Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Medincell confie son Contrat de liquidité à ROTHSCHILD MARTIN MAUREL pour animer ses actions sur Euronext Paris, conformément à la réglementation en vigueur

Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Réglementation Medincell
PRESS RELEASE

published on 09/11/2024 at 07:30, 1 year 4 months ago

Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01

Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
PRESS RELEASE

published on 09/11/2024 at 07:14, 1 year 4 months ago

Inside Information / News release on accounts, results
Antin Infrastructure Partners reports Half-Year 2024 Results showing growth in AUM, revenue, and EBITDA. Investment activity doubled, with strong financial performance and dividend payout. CEO optimistic about future opportunities

Financial Performance Dividend Payout Investment Activity Antin Infrastructure Partners Half-year 2024 Results
PRESS RELEASE

published on 09/11/2024 at 07:05, 1 year 4 months ago

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU. Positive pivotal data support Dupixent as a new targeted therapy for CSU

Phase 3 Study Dupixent CSU Chronic Spontaneous Urticaria Itch And Hives
PRESS RELEASE

published on 09/11/2024 at 07:05, 1 year 4 months ago

Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée
Dupixent : résultats positifs de l'étude de phase III confirmant l'efficacité du traitement de l'urticaire chronique spontanée non contrôlée. Nouvelle soumission réglementaire aux États-Unis

Traitement Dupixent Étude De Phase III Résultats Positifs Urticaire Chronique Spontanée
REGULATED PRESS RELEASE

published on 09/11/2024 at 07:00, 1 year 4 months ago

Strong interim results and new investments for TINC
TINC reports strong interim results with a net profit of €18.0 million and new investments totaling €50 million. The company plans to distribute a gross dividend of €0.58 per share

Net Profit Dividend Distribution TINC New Investments Interim Results
REGULATED PRESS RELEASE

published on 09/11/2024 at 07:00, 1 year 4 months ago

Strong interim results and new investments for TINC
Strong interim results with €18.0 million net profit and investments of €50 million for TINC. Plans to distribute €0.58 per share for current year

Net Profit Investments TINC Distribution Interim Results
REGULATED PRESS RELEASE

published on 09/11/2024 at 07:00, 1 year 4 months ago

Sterke tussentijdse resultaten en nieuwe investeringen voor TINC
Sterke tussentijdse resultaten en nieuwe investeringen voor TINC. TINC behaalt € 18,0 miljoen nettowinst en doet € 50 miljoen nieuwe investeringen in infrastructuur. Aandeelhouders mogen € 0,58 per aandeel verwachten

TINC Aandeelhouders Investeringen Tussentijdse Resultaten Nettowinst
PRESS RELEASE

published on 09/11/2024 at 07:00, 1 year 4 months ago

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent achieves significant improvements in disease remission and symptoms in bullous pemphigoid study. Study met primary and key secondary endpoints with beneficial steroid-sparing effect

Dupixent Bullous Pemphigoid Disease Remission Symptoms Steroid-sparing Effect

Published on 02/05/2026 at 09:05, 40 minutes ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 8 hours 10 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 9 hours 45 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 11 hours 20 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 15 hours 45 minutes ago

Lithium South AGSM Update

View all ACCESSWIRE

Published on 02/05/2026 at 09:00, 44 minutes ago

Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 45 minutes ago

Original-Research: Limes Schlosskliniken AG (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 45 minutes ago

Original-Research: Semperit AG Holding (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 45 minutes ago

Official List Notice
Published on 02/05/2026 at 09:00, 45 minutes ago

Novem Group S.A.: Q3 2025/26 shows steady Series sales

View all EQS

Published on 02/04/2026 at 18:04, 15 hours 41 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 15 hours 41 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 16 hours ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 16 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 16 hours ago

Janvier 2026

View all LES ECHOS COMFI WIRE

News